Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artes/Anika dermal filler deal

This article was originally published in The Gray Sheet

Executive Summary

Artes Medical, maker of the non-resorbable, FDA-approved injectable dermal filler Artefill, will distribute Anika Therapeutics' FDA-approved hyaluronic acid-based soft-tissue filler Elevess in the U.S. through its 42-rep sales force under an exclusive marketing agreement announced July 8. Because Artefill, which incorporates polymethylmethacrylate microspheres and bovine collagen, requires a skin test and waiting period prior to injection, doctors can use Elevess - which lasts six months - for initial correction during the Artefill skin test waiting period, Artes explains

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel